Fidelity, Valor pool $71.8M for Jeff Aronin's plan to reformulate a generic for butterfly skin disease at Castle Creek Pharma
Jeff Aronin is back.
To be sure, Aronin didn’t exactly go away. The former Marathon Pharmaceuticals CEO merely sold off a controversial drug, shuttered …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
